The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Continuous Glucose Monitoring
Abstract
This JAMA Insights discusses continuous glucose monitoring use among individuals with type 2 diabetes, including types of devices, evidence of effectiveness, and adverse effects and contraindications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CGM helps characterize the timing, amplitude, and frequency of excursions [133–139], and provides quantitative metrics such as TIR, time in hypoglycemia (TBR) and hyperglycemia (TAR), and indices of glycemic variability, which are increasingly used as clinically meaningful targets in diabetes management [140–144].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [142]
Citations
Cites
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Beck, R. W., Bergenstal, R. M., Riddlesworth, T. D., Kollman, C., Li, Z., Brown, A. S., & Close, K. L. (2019) · Diabetes Care · doi:10.2337/dc18-1444 · Cited by 793
Self-citationGlucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring
Bergenstal, R. M., Beck, R. W., Close, K. L., Grunberger, G., Sacks, D. B., Kowalski, A., Brown, A. S., Heinemann, L., Aleppo, G., Ryan, D. B., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1581 · Cited by 684
Self-citationBeck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Self-citationMartens, T., Beck, R. W., Bailey, R., Ruedy, K. J., Calhoun, P., Peters, A. L., Pop-Busui, R., Philis-Tsimikas, A., Bao, S., Umpierrez, G., et al. (2021) · JAMA · doi:10.1001/jama.2021.7444 · Cited by 543
Self-citation
Flagged first, then by citations
Research works printed but not linked: 6
- Nathan, 2024, History of the Diabetes Control and Complications Trial and its follow-up Epidemiology of Diabetes Interventions and Complications Study., Diabetes Care, 47, 1511, 10.2337/dci24-0063 · DOI
- Jancev, 2024, Continuous glucose monitoring in adults with type 2 diabetes., Diabetologia, 67, 798, 10.1007/s00125-024-06107-6 · DOI · Paper page
- Okuno, 2025, Continuous glucose monitoring metrics predict all-cause mortality in diabetes., Diabetes Care, 48, 1794, 10.2337/dc25-0716 · DOI
- Thomas, 2024, Management of outpatients with diabetes at high risk of hypoglycemia., JAMA, 331, 1145, 10.1001/jama.2024.1137 · DOI
- Raghinaru, 2022, The optimal duration of a run-in period to initiate continuous glucose monitoring for a randomized trial., Diabetes Technol Ther, 24, 868, 10.1089/dia.2022.0274 · DOI
- Diedisheim, 2023, Prevalence and description of the skin reactions associated with adhesives in diabetes technology devices in an adult population., Diabetes Technol Ther, 25, 279, 10.1089/dia.2022.0513 · DOI
Cited by
Sorted by citations
Wilmot, E., Moore, P., Sathyapalan, T., Choudhary, P., Lim, J. Z. M., Neupane, S., Crabtree, T. S., Iqbal, A., Evans, M., Rayman, G., et al. (2026) · The Lancet Diabetes and Endocrinology · doi:10.1016/s2213-8587(26)00076-8 · Cited by 5
Lara-Gálvez, D., Rubio-Almanza, M., Aparicio-Ródenas, Y., Sanchis-Pascual, D., Masdeu-López-Cerón, P., Pérez-Cervantes, V., & Merino-Torres, J. F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010034 · Cited by 3
“…care, CGM has been widely adopted as standard practice for adults using basal insulin, multiple daily injections, or continuous subcutaneous insulin infusion, as well as for youth with type 1 diabetes, owing to its demonstrated benefits for glycemic control and treatment satisfaction [13–15].”
Diabetic gastroparesis: pathophysiology and impact on insulin timing choices
Galeano, F., Tumminia, A., Oteri, V., Le Moli, R., Piticchio, T., Scilletta, S., Di Marco, M., Di Pino, A., & Frasca, F. (2026) · Endocrine · doi:10.1007/s12020-026-04693-6
Diabetes Technology Use in Adults
Coronel-Couto, G., & Stumbar, S. E. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2026.08.011
The Role of Hemoglobin A1C in the Era of Continuous Glucose Monitoring
Perlman, J. E. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.09.002
Metadata
- Authors
- Bergenstal, R. M., Martens, T. W., & Beck, R. W.
- Affiliations
- HealthPartners (US)
- Jaeb Center for Health Research (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2025-12-23
- Volume
- 334
- Issue
- 24
- Pages
- 2220
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4416581289
- Cited by
- 10
- References
- 0
- Citations by year
- 2026: 9 · 2025: 1
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, type 2 diabetes, glucose monitoring devices, device effectiveness, adverse effects, contraindications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
